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Chemistry

ALTERATION OF DNA – TRANSCRIPTION FACTOR INTERACTIONS
FOLLOWING CHROMIUM EXPOSURE
Chairperson: Dr. Kent Sugden
The effect of 8-oxoguanine in the consensus sequence of κB DNA on the binding
affinity of p50BD was determined using a 22-mer and a 30-mer double-stranded DNA
oligonucleotide containing the NF-κB binding site. The addition of a carboxyl moiety at
position 8 on guanine (creating 8-oxoguanine) was observed to change the binding
affinity of the transcription factor for the κB DNA sequences at each modified guanine
site. The protocol used a p50 binding domain protein (residues 23 to 366 from the p50
protein) and a p50 mutant protein with a single amino acid mutation of the wild type
histidine 67 to alanine 67. Both proteins were cloned as N-terminal his6-tagged proteins.
These proteins were expressed and purified as active proteins. It is known that reduction
of chromium(VI) to chromium(III) creates species such as chromium(V) and
chromium(IV) which interact with and damage DNA. An oxidative event, such a
chromium(VI) reduction to chromium(III) could allow a crosslinking of protein-bound
DNA. Redox values suggest that oxidative damage can travel to guanine-rich sites, such
as that of the consensus sequence of κB DNA. This suggested a mechanism by which a
chromium oxidative event could crosslink the DNA and protein into a binary complex
without direct chromium involvement at the site of oxidation. Furthermore the protein,
tightly bound to DNA, may compete with water to act as a nucleophile on DNA. This
binary DNA-protein complex may be covalently linked and resistant to harsh conditions,
allowing it to be visualized by HPLC or gel electrophoretic mobility shift assays. Under
our conditions, no κB DNA, either unmodified or modified with 8-oxoguanine, was
found to be bound to the p50BD protein. DNA oxidation through chromium reduction
was not found to result in crosslinked p50BD protein in a binary DNA—protein complex.
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CHAPTER 1
Introduction/Background
To explain what causes the initiation of cancer using a model other than the
mutation model, pieces of the puzzle must be assembled one at a time. For age related
diseases, such as cancer, these model pieces include chromium as an oxidant, damaged
DNA, and a transcription factor protein.
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Chromium background and chromium oxidation
The discovery of chromium is attributed to Vaquelin in 1798, as the mineral
PbCrO4 (crocoite) from Siberia,1, 2 but its use in stainless steel could date back through
history to the weapons of the Hittites (conquered by Ramsey II around 1300 B.C.).3 The
name ‘chromium’ stems from chroma (color), in reference to the wide variety of colors
of chromium compounds. Although the possible oxidation states range from –2 to +6, it
commonly exists in four valence states: Cr(0), Cr(II), Cr(III), and Cr(VI).1, 4 While the
anhydrous Cr(II) salts are relatively stable, the divalent state (II) oxidizes readily to the
trivalent (III) state.5

O
O

Cr

-

O

+6
L

O

-

CrO4

L
2-

Figure 1.1: common chromium structures:
Left – Hexavalent chromium; chromate.

L +3
L
Cr
L
L
CrL6

Right – Chromium (III)

For the human body anecdotal evidence points to the +3 oxidation state of
chromium to be important in the interaction between insulin and insulin receptor sites,
however this has not been scientifically established. It has been established that excess
chromium in the body, depending on valence states, can have unpleasant consequences
including disease and death.
What is of increasing concern with regard to human health is the anthropogenic
accumulation of chromium in the environment. Human chromium exposure is found
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both in the workplace and in the environment. Occupational exposures to chromium can
be found in welding, leather and chrome plating workers as well as stainless steel and
chrome pigment production.4
The link between chromium and cancer was established in the late 1800s with
the observation of nasal tumors in Scottish chrome pigment workers. Lung cancers were
first documented in the early 1930s in German chromate workers.1 Chromium (III) can
cause toxic effects if these particles enter the respiratory tract and lungs and act as nonspecific irritants.6 The particles are unable to penetrate membranes which results in a low
uptake of Cr(III) into cells. The carcinogenic form of chromium was found to be the +6
oxidation state, with lung cancer as the most prevalent outcome from inhalation
exposure.7, 8 Hexavalent chromium enters cells through phosphate and sulfate channels
or by phagocytosis. The +6 oxidation state is the second most stable state after the +3
state,5 and it is susceptible to reduction in cellular systems.9 While Cr(VI) does not
interact with DNA directly, there are a number of cellular reductants including
glutathione, ascorbate, cysteine, glutathione reductase, and carbohydrates that reduce
Cr(VI) to Cr(III).6, 10 With either a concentration gradient of higher anions outside the
cell’s membrane or the cells need for anions such as sulfate and phosphate, the Cr(VI)
enters through the anion channels, and is reduced to Cr(III); a concentration gradient is
maintained and the cycle repeats. In this method the cell can accumulate extremely high
levels of chromium.11
Hexavalent chromium, Cr(VI), is currently listed as “carcinogenic to humans” by
the International Agency for Research on Cancer (IARC) and the US Toxicology
Program.12 Chromium metal and Cr(III) compounds are rated IARC 3 whereas Cr(VI) is
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IARC 1.13 The ranking of IARC 3 is used for mixtures, agents and exposures for which
the evidence is inadequate to classify carcinogenicity to humans but sufficient to
conclude carcinogenicity in experimental animals. IARC 1 indicates a known human
carcinogen.14
The reduction of Cr(VI) to Cr(III) forms intermediate redox states of Cr(V) and
Cr(IV). These high-valent intermediate oxidation states of chromium are unstable and
are capable of causing DNA damage.15 Using Cr(VI) and ascorbate creates reactive
chromium intermediates and radicals that cause DNA damage.16 Intracellular
accumulation of Cr(III) has been proposed to interact with DNA to yield Cr-DNA, DNADNA, and DNA-protein crosslinks.15
While the functions of normal metabolism have been postulated to be one cause
of age related diseases,17 chromium exposure and the metabolic by-products generated
causing cellular damage by radicals have been postulated to be another cause of agerelated diseases. Cellular metabolism of chromium has the possibility to create hydrogen
peroxide (H2O2), hydroxyl radical (•OH), and superoxide (•O2-). These oxidants are all
capable of damaging proteins, DNA, RNA and other cell components.18 This pathway of
free radical oxidants from metal exposure could likely be a cause of pathogenesis. 10, 19
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DNA structure, oxidation, and 7,8-dihydro-8-oxoguanine
To investigate the second piece of the puzzle, damage to DNA, its structure and
function must be understood. The structure of DNA, deoxyribonucleic acid, was defined
by Watson and Crick in 1953 as a double helix composed of ordered sequences of the
nucleotide residues (the nucleotide bases are adenine (A), guanine (G), cytosine (C) and
thymine (T)) linked via glycosidic bond to a five carbon sugar (2’-deoxyribose); residues
are linked through phosphate moieties.20

Figure 1.2: Double-stranded B-form (regular) DNA21
The function of DNA is to be the cell’s repository of genetic information. The
DNA is wrapped and packaged into chromosomes and protected in the cells nucleus.
There is a basal level of DNA transcription for routine cellular needs. Additionally, in a
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normal functioning cell, stimulants such as radiation and viral infections elicit a cellular
response when transcription proteins bind DNA to generate RNA which can be translated
into protein. The response is to fight infection or repair cellular damage.
However, in a cell with damaged DNA, these functions and mechanisms are
affected. This damage to DNA includes but is not limited to DNA strand breaks and
modifications to DNA.

Modifications to DNA were found to primarily affect the base

guanine. The one electron redox potential of guanine is the lowest of all the nucleobases
at E˚ ≈ 1.29 (V vs. NHE) at pH 7. The other bases have higher redox potentials; A ≈
1.42, C ≈ 1.6, T ≈ 1.7 (for the nucleoside forms, etc.).18 The more negative a number, the
less likely it is to be reduced and more likely it is to be oxidized. The reactivity of
guanines toward any oxidant is also sequence specific. When guanine is located next to a
purine — especially another guanine — it is more reactive than if it was next to a 3’
pyrimidine. Furthermore, if the sequence is increased to contain more than just two
guanines (G), then the reactivity also increases. Interestingly, chromium interacts
preferentially at regions of high guanine content in double stranded DNA with GC ≈ GT
< GA < GG < GGG < GGGG (where G is the site of damage). 22 This phenomenon is
explained by a mechanism in which the highest occupied molecular orbital (HOMO)
resides on the 5’G due to π-stacking in the purine runs.23 Furthermore, this site may act
as an electron hole since oxidative damage along DNA can migrate to this location.
Electron hole migration is known to occur in double-stranded (ds)DNA strands, where
the electron hole can “travel” through DNA up to 300 base pairs to a site of high guanine
content.24
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Oxidative damage to DNA is common. Over 100 oxidatively modified bases
have been identified in DNA,25 and these are estimated to occur at a frequency of 10,000
per cell daily for a human cell.15, 17 This oxidative DNA damage has been separated into
four distinct classes, 1) abasic sites, 2) strand breaks, 3) modified bases, and 4) DNA—
protein crosslinks.26 It has been suggested ~ 1 per 40,000 guanines in the human genome
are oxidized to 7,8-dihydro-8-oxo-guanine (8-oxoguanine).26 It appears safe to assume
that 8-oxoguanine is present constitutively in every cell.

Figure 1.3A: Normal C-G base pair

Figure 1.3B: C-8-oxoguanine base pair,
with new donor/acceptor patterns

8-oxoguanine is a common guanine product under oxidizing conditions, which
includes chromium exposure.18 The normal base pairing of guanine appears, with donor
acceptor patterns (figure 1.3A, from LÆR), as hydrogen bond donor, acceptor, and
acceptor in the major groove (in Lewis acid/base form). However, 8-oxoguanine changes
the major groove donor/acceptor pattern and adds an additional acceptor bond (figure
1.3B). The specific effect of the oxidation on guanine at C8 is that the N7 transforms
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from H-bond acceptor to donor, and the C8 becomes a strong H-bond acceptor at the
oxygen (circled in red). The minor groove, as marked above, does not change in
donor/acceptor patterns.
8-oxoguanine in the sequence 5’-CCA GoCG CTGG-3’, where Go represents 8oxo modification, was crystallized in 1995 by Lipscomb, et al. (183D.pdb).27 The
divergence in structure between a regular guanine versus 8-oxoguanine is very slight in
an oligomer. The only change discerned when 8-oxoG containing DNA was overlaid
with the same sequence DNA was in residue 4 (Go) seen in the torsion angle χ from O4’C1’-N9-C4 (the glycosidic bond region) for the guanine residue location of interest.

8-oxoG

Figure 1.4: 8-oxoguanine-containing double-stranded B-form DNA21
183D.pdb,27 the 8-oxo moiety tucked behind the sugar is accessible in the major groove.
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Further oxidized lesions
The oxidative product of guanine, 8-oxoguanine, is prone to further oxidation.28
Studies on the one electron redox potential for 8-oxoguanine nucleoside suggest E˚ ≈
0.58 V vs. NHE at pH 8, less than that of guanine at pH 7, where E˚ ≈ 1.29.18 The factors
influencing the location-dependent guanine oxidation (5’-GGGG-3’) will also influence
8-oxoguanine further oxidation.
With water as the nucleophile attacking at the C5 position on 8-oxoguanine,
recent studies have indicated that guanidinohydantoin (Gh) and spiroiminodihydantoin
(Sp) are the major products of 8-oxoguanine oxidation (by chromium(VI)).29 The
chemical structures of these further oxidized lesions are shown below, with the C5
locations indicated by arrows:

H
N

O

O
N
DNA

Gh

N
H

OO
NH
NH2

NH

HN
O

N

N

DNA H

NH

Sp

Figure 1.5: Nucleophilic attack by water at C5 of 8-oxoguanine produce Gh and Sp
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Transcription factor protein chemistry
To understand DNA—protein binding and the altered protein binding affinities
with damaged DNA, transcription factor protein (TFP) biochemistry must be understood.
DNA—transcription factor protein interactions drive the sequence-specific nature of TFP
binding. TFPs can be split into two distinct categories, the general and the sequence
specific.30 General TFPs employ cellular machinery, including RNA polymerase, that
bind based on the promoter ‘start’ sequence of the TATA box AT-rich region. Unlike the
general TFPs, specific TFPs bind to particular motifs in the sequence of the promoter
region of the gene and then utilize the general TFP machinery.
Upon binding, the protein’s amino acids make specific hydrogen and electrostatic
bonding interactions. Examples are histidine with a positively charged (acidic) residue
containing an imidazole ring, and lysine, protonated under physiological conditions.
Both amino acid residues are involved in hydrogen bond interactions.

H

H

HN1

C5 C
4
C2

+

H3N C COO-

H3N C COOCH2

CH2

N3

Imidazole

+

CH2

HN1

N3

Histidine

CH2

Lysine

CH2
NH3+

Figure 1.6: Charged structures with potential to crosslink DNA

Many TFPs have been well characterized, specifically AP-1, p53, and NF-κB
which are classified as (oncogenic) activating protein, tumor suppressor protein, and
signal transducer protein respectively.30, 31, 32 The balance of activation or inactivation of
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regulation is complex; either action in excess ostensibly leads to tumorigenesis.
Mutations in transcription factor proteins, depending on the location, have the potential to
produce severe cellular consequences, eventually resulting in disease or death. However,
the exact genetic causes of disease cannot always be neatly explained by a conventional
mutation model. What is known for certain is that when control is lost over gene
expression, specifically the DNA—protein binding, the impact is seen in the gene
product.
It has emerged that several tightly controlled regulatory DNA elements of a cell,
such as the genes for NF-κB and p53, contain a consecutive run of guanines in their
promoter sites and that these areas are redox sensitive.33, 34 Many of these promoters
drive genes that are transcribed during an oxidative attack on DNA. Conserved guanine
sequences within promoter sites can be considered an evolutionary design to modulate
gene expression during an oxidative event rather than an evolutionary ‘flaw’. Logic
dictates that there is a reason that DNA has evolved to have these oxidation-prone run of
guanine regulatory elements. It is possible that the oxidized sequences recruit proteins
based on of the type of the modification, in a similar mode to non-modified sequences
which recruit transcription factor proteins based on cellular needs.
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Covalent crosslinking

DNA-protein binding has been investigated for many decades. Mammalian
DNA-protein crosslink existence was established in the late 1980s.35 Much is known
about chromium reactions within a cell;6 it is established that Cr(VI) is carcinogenic and
that a reduced form of chromium(VI) creates DNA-protein crosslinks, but the mechanism
of how crosslinks are formed remains a mystery. Determining the exact role of
chromium, Mattagajasingh and Misra suggested that, “…the nature of chromate-induced
DNA-protein crosslinks is not fully resolved.”36 Currently chromium is thought to form
ternary adducts with DNA in cellular systems. 6, 36, 37,

38

In this conventional model only

Cr(III) is directly involved in the crosslink and both DNA and proteins are thought to be
ligands of the chromium metal complex.37
The theory of Mattagajasingh and Misra was that intracellular reduction of
Cr(VI) to Cr(III) creates species such as chromium(V) and chromium(IV), and reactive
oxygen species. These species mediate the crosslinks directly in ternary structures:
DNA-Cr-protein, where the DNA and the protein are metal ligands. Recent papers
further propose that reduced forms of chromium are unstable crosslinks; that Cr(V) and
Cr(IV) will not be found in stable ternary covalent crosslinks.38 Yet many factors at the
DNA-protein interface could allow a chromium oxidative event to crosslink the DNA and
protein without direct chromium involvement. Therefore, in the reduction of the forms of
Cr(V) or Cr(IV) to Cr(III), the DNA could be oxidized at the protein hydrogen-bound 8oxoguanine DNA thereby covalently crosslinking the DNA—protein in a binary
complex, rather than a ternary complex.
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Many pieces of the puzzle come together to form a theory supporting a binary
covalent crosslink of DNA and protein. First, it has been seen that modified DNA can
recruit and hydrogen bond protein. When protein is bound to modified DNA it
potentially excludes the water – the nucleophile required to generate Gh or Sp under
further oxidizing conditions. Next, chromium can interact preferentially at these gene
promoter regions of DNA with high guanine content, based on the redox potentials of
both the chromium and the guanine-rich area, and further oxidize the DNA.
Consequently, when chromium performs an oxidative event on the modified DNA, the
protein can act as a nucleophile, and the oxidation could potentially crosslink the DNA—
protein together in a binary complex. The theory that this binary complex is created from
covalent crosslinking of modified DNA to protein by chromium oxidation incorporates
two of the classes of oxidative DNA damage (the modified base and the DNA—protein
crosslink). This binary covalent linkage may also block transcription by shielding the
modified base from repair which would have a long-term impact on global gene
expression. The binary covalent link would explain the initial causes of disease states
beyond that of the simplified mutation model. Furthermore, this method of DNA—
protein crosslinking explains a role of chromium in oxidative events.
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Investigations into DNA—protein crosslinking

The investigations performed to elucidate the exact mechanism of crosslinks have
involved an NF-κB DNA oligonucleotide, lab-generated protein, and several species of
chromium. The dsDNA oligonucleotide has a run of four guanines; the non-modified
(control) strand is utilized along with versions of a single modified guanine in each of the
four sites.
The first step in elucidating crosslinks was to determine the electrostatic and
hydrogen bond interactions of the protein with each of the dsDNA strands. Once
established, the chromium species could be added to determine the effect of chromium
oxidation on non-modified DNA—protein as well as modified DNA—protein binding.
To determine that bonding was covalent rather than electrostatic, a denaturing
environment was used to select for covalent bond resistance to degradation.
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CHAPTER 2
p50 Protein background and interactions:
History of NF-κB:
Nuclear factor of the κ-light chain of B cells (NF-κB) controls gene expression
through recognition of κB sequences in the promoter regions of DNA.1 The NF-κB
family of proteins are transcription factor proteins that regulate a wide range of responses
to infection and inflammation. The proteins mediate cell proliferation, cell
transformation, angiogenesis, cell invasion, cell immunity, apoptosis, and hematopoiesis.2
NF-κB is part of a larger family of Rel proteins, containing Rel homology domains that
bind DNA as hetero- or homodimers in the nucleus.3 The active dimer exists in an
inactive state as a heterotrimer in the cytoplasm where the dimer is bound with an IκB
inhibitor protein (IκB-α, IκB-β, IκB-γ, Bcl-3, and cactus). Activation causes
phosphorylation and ubiquitination of the inhibitory protein and the free NF-κB dimer
then translocates into the nucleus. The five members of the NF-κB are p65 (RelA), RelB,
c-Rel, p50 (NF-κB1) and p52 (NF-κB2). The most common NF-κB protein is the
p50/p65 heterodimer.4
The proteins bind DNA sequences, called κB DNA enhancer elements. The
generic κB DNA consensus site, which will bind all NF-κB proteins, has been determined
to be a ten base pair sequence, 5’-GGG RNW YYC C-3’ (where N is any nucleotide, Y is
pyrimidine, R is purine, and W is A or T).5 Hundreds of variations of this κB DNA
sequence exist in gene promoters.5 Most dimers can associate with varying binding
affinities to different κB DNA sites. These small differences in binding affinities for κB
sequences can have an impact on the expression of genes, implying that the role of the
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DNA sequence and its conformation has an important responsibility in gene expression
with the NF-κB protein.5 Huang et al. proposed to organize the κB sites into two distinct
classes, class I for p50 and p52 hetero- and homodimer binders, and class II for p65 and cRel hetero- and homodimers.5
The ten base pair consensus sequence contains the class I κB site of 5’-GGG RN3’ half-site and the class II κB site of 5’-YYCC-3’ half-site. The most 5’-G for class I κB
is in contact with a histidine side chain that is exclusive to p50 and p52 which gives rise
to sequence specificity. For p65 and c-Rel, the histidine in the protein sequence is
replaced with an alanine. The impact for these sequence specificities is that the
homodimers of p50 and p52 bind optimally to 11 base pair κB sites, heterodimers with
p50 or p52 prefer 10 base pair sites, and homodimers of p65 or c-Rel prefer 9 base pair
κB sites.5
Ghosh et al.6 and Müller et al.7 crystallized residues 39-364 for the mouse p50
protein and residues 2-366 for the human p50 protein, respectively. For Ghosh et al.,
these truncated protein constructs bound both the κB sequence and I-κB. For Müller et al.
the truncated protein was the most stable fragment that was proteolytically cleaved from
p105 to create p50 ending at the nuclear localization signal (Figure 2.1).
The Rel homology domain folds into two subunits, the larger N-terminal domain
which contacts DNA base pairs and the smaller C-terminal domain which is responsible
for dimer formation and DNA phosphate contact. Residue proline 43 marks the
beginning of the Rel homology domain; residues 160-205 form an α-helical like structure
within the Rel domain but are not part of the domain. Residues 250 – 366 mark the Cterminal domain and residue 366 marks the end of the nuclear localization signal.
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Residues 244-250 form a flexible linker region between the two domains which is not
stabilized by H-bonds or hydrophobic contacts which makes it ideal as a flexible hinge for
the protein to bind to or dissociate from DNA.

Figure 2.1: Structure of p105/p50 Adapted from Gilmore, et al. (1996) Oncogene 13,
1367-1378. 8 RHD – Rel Homology Domain; PK – protein kinase A recognition
sequence; NTS – nuclear targeting sequence also known as nuclear localization signal.
Protease cleaves as indicated to form p50 from p105, leaving the N-terminus intact.

DNA recognition
Both the N- and the C-terminus contact DNA. The protein binds in the major
groove and in the p50 homodimer, at the dimer interface, the C-terminus domains wrap
around the DNA for phosphate interactions. The N-terminal domain covers the 5’GGGGAC-3’ half site. The C-terminal domain is composed of six variable loops. The
N-terminal domain contains nine variable loops, two of which comprise the κB DNA
recognition loops, allowing for flexibility in protein conformation and binding DNA. The
N-terminal domain does not contribute to the protein dimerization interface. Specific
DNA recognition by p50 is shown in Figure 2.2, page 23. When p50 binds DNA, there a
slight deviation from B-form DNA with the unwinding and a slight bend of DNA. There
is no extreme distortion of DNA by the protein.6
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Site-specific changes to p50BD to create a mutant protein
We have previously shown that a 22-mer double-stranded DNA sequence (5’AGT TGA G1G2G3 G4AC TTT CCC AGC C-3’) with an 8-oxoguanine in each of the
numbered guanines sites gave discrete p50 protein binding affinities depending upon the
location of the 8-oxoguanine lesion.9 The histidine in position 67 of the human p50
protein is important in DNA binding as the histidine would contact the 8-oxoguanine at
position G1. The C5 of 8-oxoguanine, a vinyl carbon, could be subject to nucleophilic
attack by either of the histidine’s nitrogens at position 67 during an oxidative event (see
Figure 2.3). As an 8-oxoguanine in specific NF-κB sequence positions could impact
binding affinities, a mutant was engineered with the histidine changed to an alanine in
order to mimic p65 or c-Rel binding. In addition, the engineered p50 protein consisted of
only the DNA binding domain, residues 23-366.
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Table 2.1: DNA and protein sequence comparisons of the p50 binding domain protein
and p50 mutant protein
Comparison of protein sequences
p50BD
GAA GGC CCA TCC CAT GGT GGA CCT GGT
HTIFNPEVFQPQMALPTDGPYLQILEQPK
Translation of
p50BD (1 letter Q R G F R F R Y V C E G P S H G G L P G A S S E K N K K
SYPQVKICNYVGPAKVIVQLVTNGKNIH
protein code)
LHAHSLVGKHCEDGICTVTAGPKDMVV
GFANLGILHVTKKKVFETLEARMTEACI
RGYNPGLLVHPDLAYLQAEGGGDRQLG
DREKELIRQAALQQTKEMDLSVVRLMFT
AFLPDSTGSFTRRLEPVVSDAIYDSKAPN
ASNLKIVRMDRTAGCVTGGEEIYLLCDK
VQKDDIQIRFYEEEENGGVWEGFGDFSP
TDVHRQFAIVFKTPKYKDINITKPASVFV
QLRRKSDLETSEPKPFLYYPEIKDKEEVQ
R K R Q K L Stop Stop
P50H67A
Translation of
p50H67A (1
letter protein
code)

GAA GGC CCA TCC GCA GGT GGA CCT GGT
HTIFNPEVFQPQMALPTDGPYLQILEQPK
QRGFRFRYVCEGPSAGGLPGASSEKNKK
SYPQVKICNYVGPAKVIVQLVTNGKNIH
LHAHSLVGKHCEDGICTVTAGPKDMVV
GFANLGILHVTKKKVFETLEARMTEACI
RGYNPGLLVHPDLAYLQAEGGGDRQLG
DREKELIRQAALQQTKEMDLSVVRLMFT
AFLPDSTGSFTRRLEPVVSDAIYDSKAPN
ASNLKIVRMDRTAGCVTGGEEIYLLCDK
VQKDDIQIRFYEEEENGGVWEGFGDFSP
TDVHRQFAIVFKTPKYKDINITKPASVFV
QLRRKSDLETSEPKPFLYYPEIKDKEEVQ
R K R Q K L Stop Stop

The binding affinities for the p50 binding domain protein with the five
oligonucleotide sequences, four of which contain 8-oxoguanine modifications, were
investigated. For the p50H67A mutant with the control and the 8-oxoguanine DNA
modified at position G1, the binding affinities were investigated. An apparent binding
constant, Kapp, was determined for each protein-DNA modification as the point where the
fraction bound equals 50% graphically.
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Materials and methods:
Deoxyribonucleotides. Unmodified oligonucleotides with the κB consensus sequence
were obtained from IDT DNA (Coralville, IA). Modified 22-mer DNA sequences
containing an 8-oxoguanine in the NF-κB protein p50 homodimer consensus sequence
(5’-AGT TGA G1G2G3 G4AC TTT CCC AGC C-3’, where the bold bases indicate the
consensus sequence and the G1-4 indicate positions of 8-oxoguanines in the recognition
sequence) were obtained from TriLink Biotechnologies (San Diego, CA). Modified 30mer DNA sequences containing the sequence 5’- TCC GCT G1G2G3 G4AC TTT CCG
CGG AGA CTC TAG -3’ (again the bold bases indicate the consensus sequence and the
G1-4 indicates positions of 8-oxoguanines in the recognition sequence) were also obtained
from TriLink Biotechnologies. HPLC purification of the 22-mer oligonucleotide strands
was performed using a Dionex DNAPac PA-100, 4 mm x 250 mm anion exchange
column. Elution was accomplished with a linear gradient of 90% mobile phase A (10%
aqueous acetonitrile) and 10% mobile phase B (1.5 M ammonium acetate (pH 6.2), 10%
acetonitrile) to 100% mobile phase B over the course of 22 minutes. The 30-mer
oligonucleotide was purified in a similar manner, however mobile phase A also contained
500 mM NaCl and elution was accomplished with a linear gradient of 90% A and 10% B
to 100% mobile phase B over 30 minutes. Column elutions of oligonucleotides were
observed by diode array at 268 nm. The single-peak elution of oligomer was evaporated
to remove the volatile acetonitrile, eluted through a BioRad chromatography column 6
and stored at -20˚C until needed for testing. The NaCl from the 30-mer oligonucleotides
was removed by elution through a BioRad chromatography column 30. Standard methods
were employed to 5’- 32P end-label specific oligomers. The control or 8-oxoguanine
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containing single stranded DNA was incubated with polynucleotide kinase and 10 µCi of
32

P-γ-ATP for 30 minutes. Column elutions with a Micro Bio-Spin 6 chromatography

column from BioRad (Hercules, CA) removed the enzyme and unincorporated
nucleotides. The radiolabeled single stranded DNA was annealed to complement DNA
by heating to 95˚C and slowly cooling 1˚C / 1 minute using a Peltier Thermal Cycler from
MJ Research (BioRad, Waltham, MA).
NF-κB p50BD Transcription Factor Protein. The p50 binding domain sequence from
residues 23 to 366 was created using an I.M.A.G.E. clone of the p105 protein as a PCR
template. The p50 binding domain region was amplified by PCR using primers from IDT
DNA. The p50BD DNA contained engineered restriction sites EcoR I and Xba I at the 5’and -3’ ends respectively. These primers were p50EcoR1H23For (5’-GGA ATT CCA
TAC AAT AAT TAA TCC AGA A-3’) and p50Rev (5’-AGG CTC TAG ATT TCA TCA
GAG CTT CTG ACG TTT CCT-3’). The pPROEX HTa plasmid (Invitrogen) was
transformed into competent GW1678, a dam- and dcm- E. coli strain (E. coli Genetic
Stock Center). The E. coli were made competent by picking colonies from freshly
streaked plates and growing overnight at 37˚C in LB media; 2 mL of the overnight culture
was then grown in 100 mL of LB-media at 37˚C until OD260 was 0.3 to 0.4. The culture
was collected in 50 mL tubes and centrifuged at 4000 rpm for 15 minutes at 4˚C, and then
the liquid was drained. The pellet was re-suspended in approximately 16.5 mL solution A
(100 mM RbCl, 50 mM MnCl2·H2O, 30 mM KCH3COOH, 10 mM CaCl2·2H2O, 15%
(v/v) glycerol, pH 5.8 by 0.2 M CH3COOH, and filter sterilized), incubated on ice for 30
minutes and centrifuged at 4000 rpm for 15 minutes at 4˚C. The pellet was re-suspended
in approximately 4 mL solution B (10 mM MOPS, 10 mM RbCl, 75 mM CaCl2·2H2O,
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15% (v/v) glycerol, pH 6.8 with NaOH and filter sterilized) and incubated on ice for 15
minutes. Aliquots were distributed into microcentrifuge tubes, flash frozen in dry
ice/ethanol mixture and stored at -80˚C.10 The plasmids were amplified in this strain to
provide a non-methylated plasmid as subsequent restriction enzymes are inactive on
methylated DNA. The PCR insert and plasmid were cut with EcoR I and Xba I, ligated
with Quick Ligase (New England Biolabs, Ipswich, MA) at room temperature for five
minutes, chilled on ice, and then transformed into XL-10 Gold Ultracompetent cells
(Stratagene, La Jolla, CA). The transformations were performed by mixing gently 100 µL
of competent cells in ice-cold 14 ml BD Falcon polypropylene round-bottom tubes with
1.7 µL β-mercaptoethanol (1.42 M) over 10 minutes. The ligation mixture was added to
the tubes (130 ng, ~3 µL) and the mixture was incubated on ice for 30 minutes. The cells
were heat-pulsed for 45 seconds at 42˚C, and chilled on ice for 2 minutes. NZY+ media
(900 µL, 42˚C, NZY+: 10 g NZ amine, 5 g yeast extract, 5 g NaCl, deionized H2O to 1 L,
pH 7.5, autoclave. Prior to use a 12.5 mL filter sterilized solution of 1M MgCl2, 12.5 mL
1M MgSO4, and 20 mL 20% (w/v) glucose was added and the cells were incubated at
37˚C for 1 hour with 225 rpm shaking. Approximately 200 µL competent transformed
cells were spread on fresh LB-ampicillin 3% agar LB plates and incubated overnight at
37˚C. Insert verification by PCR was performed before sequencing using the procedure
that follows. Ten clones that grew on the ‘plasmid + insert’ plate were isolated using a
QIAprep kit (Qiagen, Valencia, CA). The plasmid DNA, containing insert was grown
overnight in 15 mL tubes at 37˚C in LB media after picking colonies from the ‘plasmid +
insert’ plates. The culture was centrifuged at 4000 rpm for 15 minutes at 4˚C, the liquid
was drained, and the pellet was frozen at -20ºC. The plasmid DNA was isolated using a
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Qiagen miniprep kit according to manufacturer’s directions. The plasmid DNA
concentrations for the ten clone samples were determined by measuring OD260/280; 10 ng
aliquots from each of the ten plasmid samples were PCR incubated with the forward and
reverse cloning primers described earlier and then run on a 1.2% agarose gel. Two
successful clones showing the insert were selected for sequencing to verify the presence
of insert and to ensure the clone was error free and then transformed into BL21 (DE3)
expression cells (Stratagene). Sequencing primers used were the p50EcoR1H23For,
p50Rev, p50seqfor (5’-GAC AAA GTT CAG AAA-3’) and p50seqrev (5’-GAT CCC
ATC CTC ACA-3’). The cell transformation into the BL21 (DE3) E. coli was similar to
the procedure for the XL-10 Gold Ultracompetent cells except the media used was room
temperature SOC (20g tryptone, 5 g yeast extract, 0.5 g NaCl, deionized H2O to 1 L,
autoclave; added prior to use, filter sterilized 10 mL of 1M MgCl2, 10 mL 1M MgSO4, 2
mL 20% (w/v) glucose).
Protein mutations. A Quikchange® site-directed mutagenesis kit (Stratagene) was used
to create the histidine to alanine mutation. This kit allows for site-directed mutagenesis in
double-stranded miniprep plasmid DNA. The p50BD (binding domain) plasmid DNA
was incubated with complementary oligonucleotide primers containing the mutation
sequence. The forward primer H64Afor (5’-TAT GTG AAG GCC CAT CCG CAG GTG
GAC TAC CTG GTG-3’) and reverse primer H64Arev (5’-CAC CAG GTA GTC CAC
CTG CGG ATG GGC CTT CAC ATA -3’) were extended with PfuTurbo DNA
polymerase during temperature cycling. The primers created new, mutated plasmids
having nicks/non-overlapping single strand breaks that were capable of transformation
into competent cells. The products were Dpn I endonuclease treated to remove
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methylated and hemimethylated DNA (only the parental plasmid DNA is methylated).
This enzyme targets 5’-GmATC-3’ sequences. The final step was the vector DNA
transformation into XL1-Blue supercompetent cells. Fresh LB-ampicillin 3% agar plates
with IPTG (isopropylthio-β-D-galactoside) and X-gal (5-bromo-4-chloro-3-inodlyl-β-Dgalactopyranoside) were prepared; the plates were incubated at 37˚C for greater than 16
hours to allow for blue colonies to evolve indicating a successful transformation. Plasmid
DNA for p50H67A was isolated as described earlier and PCR incubated with the
p50EcoR1H23For and p50Rev primers and run on a 1.2% agarose gel. One successful
clone showing the insert was selected for sequencing to verify insert and transformed into
BL21 (DE3) protein expression cells (Stratagene).
Protein purification. The expression plasmids, in BL21 (DE3) cells, were grown to an
OD600 of 0.3-0.6 at 37˚C in LB media containing 25 µg/mL ampicillin, as the pPROEX
HTa contains an ampicillin resistance cassette. Cells were induced with IPTG to a final
concentration of 0.1 mM and incubated for 4 hours at 37˚C. Cells were then harvested by
centrifugation at 4˚C and 5,000 rcf, and frozen at -20˚C for later use. After thawing on
ice, cells were lysed using the BugBuster® protocol and reagent (Novagen, 5 mL reagent
per gram wet cell paste), lysozyme (Sigma, 0.5 mg per gram wet cell paste), Benzonase
nuclease (Novagen, 1 µL per mL BugBuster® reagent), and protease inhibitor cocktail
(Roche, 1 tablet dissolved in 2 mL H2O, use 0.2 mL per 5 mL extraction reagent). Cell
lysate was filtered through a Ni-NTA column (Qiagen). Protein was washed with
Solution A and B (50 mM NaH2PO4, 300 mM NaCl, with 10 mM and 20 mM imidazole
respectively) and eluted with Solution C (50 mM NaH2PO4, 300 mM NaCl, 250 mM
imidazole). The elution fraction was de-salted using a Microcon YM-10 and eluted into
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protein storage buffer (20 mM HEPES, 50 mM NaCl, pH 7). An aliquot was reserved for
BCA protein concentration analysis (BCA kit, Pierce, Rockford, IL), and the remaining
sample was diluted in half with protein storage buffer containing 40% glycerol, aliquoted
into 15-25 µL sub-samples depending on protein concentration, and stored at -80˚C.
Electromobility Shift Assay (EMSA or gelshift). DNA-protein binding reactions were
performed using 2.6 µM 5’-32P radioactive-labeled DNA which had been annealed to its
complement to create double stranded DNA (dsDNA). The reaction buffer for the DNAprotein binding was acquired from Promega [buffer: 20% glycerol, 5 mM MgCl2, 2.5 mM
EDTA, 2.5 mM DTT, 250 mM NaCl, 50 mM Tris-HCL, pH 7.5, 0.25 mg/mL poly(dIdC)]. The DNA and protein were allowed to react for 20 minutes before running on a
polyacrylamide gel; either a native 4% polyacrylamide gel or a 6% Invitrogen pre-poured
retardation gel. Additionally, glycerol (1 µL, 40%) was added to all reaction mixes to
increase density and help with sample loading. Unless a free well was available for dye
only, the sample ‘DNA only’ was the only well to have loading dye added in order to
minimize any interference of the dye with the DNA and protein binding interactions. The
gels were run at 250-300 V for ~10 minutes. The gel shifts were analyzed by
autoradiography (Kodak).
Data Analysis. The EMSA analysis of binding affinity for the control and the 8oxoguanine modified oligonucleotides was performed using GS 800 Calibrated
Densitometer from BioRad, by integrating the area for each band and dividing the area of
the protein-bound DNA by the total area of the free and bound DNA bands to yield a
percent bound. The software used was PDQuest 2-D gel analysis software to scan the gel
image and Quantity 1 analysis software to determine the physical area to integrate. The
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apparent dissociation constant Kapp was determined as the point where the fraction bound
equals 50% graphically.
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Results:
Cloning and mutagenesis of the p50 DNA binding domain
The p50BD PCR product ligated into pPROEX HTa was transformed into XL-10
Gold Ultracompetent cells as these cells are engineered for superior uptake efficiency of
plasmid DNA. For protein expression the plasmid was transformed into BL21 (DE3)
cells. The presence of the insert was confirmed by PCR using the original cloning
primers to amplify an ~1000 base pair fragment from the isolated plasmid (see arrow
pointing to 1000 base pair molecular marker, Figure 2.4). Six of the first ten clones (5-10,
Figure 2.5) contained insert and four did not (1, 3, 4, and 11). The lane marked ‘0’ is a
template-free PCR control lane.

1500
1000
500

Figure 2.4: PCR of p50BD clone, arrow at molecular marker 1000 base pairs.
For the mutant of p50BD, p50H67A, to confirm the presence of insert, PCR was
performed using the original p50BD cloning primers. Figure 2.5 indicates that all the
clones loaded onto the gels contained insert of the correct size ~ 1000 base pairs (see
arrow at 1000 base pair molecular marker). All seven clones selected (1-7, Figure 2.5)
contained insert. The lane marked ‘0’ is a template-free PCR control lane.
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Figure 2.5: PCR of p50H67A, arrow at molecular marker 1000 base pairs.
The Chromas sequencing determined that the clone p50BD DNA was error free.
The mutation DNA, p50H67A, was also found to be in agreement with the expected
sequence and error free (see Table 2.1, page 25, and Figure 2.6).

A

B

Figure 2.6: Sequence of proteins at mutation site
A: (top) sequencing of p50BD
B: (bottom) sequencing of p50H67A (area circled in red, 3 base mutations underlined).
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Expression of the wild type and mutant p50BD protein
Transformed BL21(DE3) cells containing p50BD or p50H67A plasmids were
grown to OD600 of 0.3-0.6, induced with IPTG, and incubated for 4 hours at 37˚C. The
proteins were purified with a Ni-NTA column as described in Materials and Methods.
The proteins were washed with Solution A and an aliquot was collected (W1 in Figure 2.7
for p50BD). The second wash, W2, of the column-bound protein with Solution B
removed trace protein impurities (see W2, Figure 2.7). The protein elution was
performed using two volumes of Solution C and aliquots show a band at the correct
molecular weight for p50BD, 42,400 Da (band at E1 and E2, Figure 2.7). The elution
fraction E1 was de-salted using a Microcon YM-10, eluted into protein storage buffer, and
stored at -80˚C.

Figure 2.7: p50BD protein purification. Protein elution by imidazole at E1 and E2.
The elution of p50H67A was performed using two volumes of Solution C and
aliquots show the molecular weight of p50H67A, 42,400 Da (band at E1 and E2, Figure
2.8). The elution fraction was de-salted using a Microcon YM-10, eluted into protein
storage buffer, and stored at -80˚C.
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Figure 2.8: p50H67A protein purification. Purified p50H67A protein elution at E1, with
some elution at W2 and E2.
DNA-protein interactions.
To investigate DNA-protein binding, oligonucleotides were ordered from IDT DNA and
TriLink DNA. The “control” sequences for the 22-mer and 30-mer oligonucleotide
strands represents unmodified DNA and provides a basis for determining the ratio of
DNA to protein for a gel shift. The 30-mer oligonucleotide sequences were used for
binding comparisons of mutant protein to wild type binding domain protein. An 8oxoguanine modification was made at every guanine indicated by O. In this manner, each
guanine in the consensus sequence had its modification evaluated by binding affinity.
Table 2.2: Sequence of 22-mer and 30-mer DNA; bold at the consensus site. Table
adapted from Hailer-Morrison, et al (2003) Biochem. 42, 9761-9770. 9
Oligomer strands, O indicates 8-oxoguanine position
22-mer control
5’-AGT TGA G1G2G3 G4AC TTT CCC AGC C-3’
22-mer modified 5’-AGT TGA G1OG2G3 G4AC TTT CCC AGC C-3’
5’-AGT TGA G1G2OG3 G4AC TTT CCC AGC C-3’
5’-AGT TGA G1G2G3O G4AC TTT CCC AGC C-3’
5’-AGT TGA G1G2G3 G4OAC TTT CCC AGC C-3’
30-mer control
5’-AGT TGA G1G2G3 G4AC TTT CCC AGA CTC TAG-3’
30-mer modified 5’-TCC GCT G1OG2G3 G4AC TTT CCG AGA CTC TAG-3’
5’-TCC GCT G1G2OG3 G4AC TTT CCG AGA CTC TAG-3’
5’-TCC GCT G1G2G3O G4AC TTT CCG AGA CTC TAG-3’
5’-TCC GCT G1G2G3 G4OAC TTT CCG AGA CTC TAG-3’
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Interaction of the 22-mer κB-DNA oligomer control sequence with p50BD:

B

A
Figure 2.9: 22-control κB DNA with p50BD.
Lanes 1-8: dsDNA + p50BD (0, 0.457, 0.914, 1.37, 1.83, 2.29, 2.74, and 3.20 µM protein)
Electrophoretic mobility shift assays show DNA binding to protein visualized by
autoradiography. The bound DNA-protein (arrow B in figure 2.9) is of higher molecular
weight due to electrostatic/hydrogen bond interactions and this entity moves more slowly
through a gel than free oligomer (arrow A in figure 2.9). Figure 2.9 also shows that the
protein is active and binds to the κB DNA sequence. An approximately 50% shift of the
DNA is accomplished using 0.457 µM p50BD protein (lane 2 as compared to zero shift
from lane 1, no protein) and a complete shift with 0.914 µM protein (lane 3). Excess
protein confirms the 100% shift of 0.914 µM p50BD (lanes 4 – 8, Figure 2.9).
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Interaction of the 22-mer κB modified at G1 DNA sequence with p50BD:

B

A
Figure 2.10: 22G1 κB DNA with p50BD.
Lanes 1-10: dsDNA + p50BD (0, 0.471, 0.942, 1.414, 1.885, 2.356, 2.827, 3.298, 3.769,
and 4.241 µM protein).
The 8-oxoguanine modification at G1 for the 22 base pair oligomer (Figure 2.10)
shows that the protein does not bind as well to the modified strand as it does for the
control. In fact, the same amount of protein that would 100% shift unmodified κB DNA
sequence – lane 3, ~ 1 µM, figure 2.9 – will only shift the 22-mer with an 8-oxoguanine at
position G1 by approximately 25%. A complete shift is not seen until lane 9, with 3.769
µM of protein, which is four times as much protein as unmodified DNA requires.
Interaction of the 22-mer κB modified at G2 DNA sequence with p50BD:
Two distinct bands were observed (Figure 2.11) when p50BD protein is incubated
with a 22-mer κB sequence modified in the G2 position with an 8-oxoguanine. These
results indicate that the monomer can bind the maximum amount of 100% of the DNA
(arrow B). At high protein concentrations a putative p50BD dimer is at a still higher
molecular weight (DNA-p50BD2) and this second band appears (Figure 2.11, arrow C).
As the amount of protein is increased, the putative dimer begins to bind the 22G2 κB

39
DNA and the amount of DNA bound by the monomer begins to decrease (Figure 2.11,
lanes 6-9, see arrows B and C).
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Figure 2.11: 22G2 κB DNA with p50BD.
Lanes 1-9: dsDNA + p50BD (0, 0.471, 0.942, 1.414, 1.885, 2.356, 2.827, 3.298, and
3.769 µM protein).

Interaction of the 22-mer κB modified at G3 DNA sequence with p50BD:
Only one faint binding band is observed (Figure 2.12) when p50BD protein is
incubated with a 22-mer κB sequence modified in the G3 position with an 8-oxoguanine.
These results indicate that the p50BD can only bind a limited amount of κB DNA with an
8-oxoguanine in the G3 position (Figure 2.12, see arrow B). A large residual amount of
unbound DNA remains (lanes 4-9, arrow A).
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Figure 2.12: 22G3 with p50BD.
Lanes 1-9: dsDNA + p50BD (0, 0.471, 0.942, 1.414, 1.885, 2.356, 2.827, 3.298, and
3.769 µM protein)
Interaction of the 22-mer κB modified at G4 DNA sequence with p50BD:
8-oxoguanine modified at position G4 binds p50BD protein in a similar manner to
the above gels with p50BD and κB DNA (Figure 2.9-2.12); unlike the 22-mer G2 (Figure
2.11), there is only one binding band is clearly observed (Figure 2.13), but it is possible
that an unresolved second band for the dimer exists in lanes 7-10. These results indicate
that the p50BD binds κB DNA with an 8-oxoguanine in the G4 position with an affinity
close to that of unmodified DNA (Figure 2.13, arrow B). A small residual amount of
unbound DNA remains (lanes 4-9, arrow A). For the densitometry analysis, the amount
of protein required for each shift of DNA was divided in half as the concentration of DNA
was 2x (or 0.52 µM). It was assumed that twice as much protein was required for twice
as much DNA, thus for half the amount of DNA (0.26 µM) only half the amount of
protein would be required to create the same DNA shifts.
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Figure 2.13: 22G4 with p50BD.
Lanes 1-10: dsDNA (concentration is 2x, 0.52 µM) + p50BD (0, 0.471, 0.942, 1.414,
1.885, 2.356, 2.827, 3.298, 3.769 and 7.068 µM protein)
Table 2.3: Densitometry for 22-mer κB sequences and p50BD
% of DNA shifted by p50BD
p50BD (µM)
Control
8-oxoG1
8-oxoG2
0
2.208424
1.060578
2.955006
0.236
0.471
36.58448
4.076286
57.51619
0.707
0.942
83.29771
23.92229
83.51295
1.178
1.414
91.06419
23.92229
99.06544
1.885
52.26755
2.356
52.26755
2.827
57.80033
3.298
60.45242
3.769
90.70031
4.241
100

8-oxoG3
0.732107
4.303915
11.83553

8-oxoG4
1.577256
21.78485
47.78349
72.54122
91.22873
99.82418

13.11185
12.27109
14.74826
14.90688
12.75896
22.96632

Lane 1 corresponds to zero µM p50BD protein on the gels shown from Figure 2.9 to
Figure 2.13; the pattern was that lane 2 up to lane 10 increased in increments of ~ 0.471
µM (200 ng) p50BD protein. The analyses of the densitometries for only Figure 2.9 were
rounded up to the nearest hundred of ng of protein for Kapp analysis which changed the
µM concentrations; for example 194 ng protein became 200 ng (0.457 µM Æ 0.471 µM),
and 388 ng became 400 ng (0.914 µM Æ 0.942 µM), and 582 ng became 600 ng (1.371
µM Æ 1.414 µM). The analysis of Figure 2.13 assumes that twice the concentration of
modified DNA requires twice the concentration of protein to elicit the shifts. For the Kapp
calculations and Table 2.3, the values for the protein concentrations are divided in half
and reported in µM values.
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Interaction of the 30-mer κB DNA control oligonucleotide sequence with p50BD:
For Figure 2.14, a greater than 90% shift of the DNA is accomplished using 0.457
µM p50BD protein (lane 3 as compared to zero shift from lane 1, no protein) and a
complete shift with 0.914 µM protein (lane 4). These concentrations of protein required
to shift similar amounts of 22-mer κB DNA are exactly the same; 0.914 µM protein are
required to have a 100% shift for the 22-mer control (Figure 2.9, lane 3). However, in no
situation with the 30-mer κB DNA was there ever a second DNA shift due to monomeric
and dimeric protein binding interactions. Excess protein confirms the 100% shift of 0.914
µM p50BD (lanes 4 – 7).
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Figure 2.14: 30-mer control κB DNA and p50BD.
Lanes 1-7: dsDNA + p50BD (0, 0.229, 0.457, 0.914, 1.371, 1.828, and 2.285 µM protein).
Interaction of the 30-mer κB DNA modified at guanine positions G1, G2, and G3
sequences with p50BD:
The side-by-side comparison shows that the presence and location of the 8oxoguanine modification completely determines the p50BD protein apparent binding
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affinity (Figure 2.15). This figure shows clearly that 30-mer G3 modification has the
poorest binding compared to the 30-mer control, G1, and G2 modified DNA.

1 2 3 4 5

1 2 3 4 5

1 2 3 4 5

1 2 3 4 5

Figure 2.15: 30-mer dsDNA (all 2.6 µM); Control, 8-oxo G1, G2, & G3 with p50BD
Lanes 1-5: 0, 0.457, 0.914, 1.371, and 1.828 µM p50BD.

The 22-mer 8-oxoguanine modified at position G2 κB DNA showed monomeric
p50BD protein binding at 100% and then dimeric protein binding at higher concentrations
of protein (2.356 µM protein, lane 6, Figure 2.11). Figure 2.15 for 8-oxoguanine 30-mer
modified at position G2 does not include a lane of 2.356 µM protein, the highest amount
of protein used was 1.828 µM; it is possible that a higher concentration of protein (~2.356
µM) could elicit a dual banding of dimeric and monomeric protein. It is feasible that the
flanking regions of the oligonucleotide for the 22-mer as compared to the 30-mer
influence the binding specificities for monomer versus dimer for modified κB DNA.
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Table 2.4: Densitometry for 30-mer κB sequences and p50BD
% of DNA shifted by p50BD
p50BD (µM)
30-mer control
30-mer G1
30-mer G2
0
0
0
0
0.457
59.4802
1.0042
1.07666
0.914
99
29.413
9.95949
1.371
99.9
31.989
22.8742
1.828
53.371
35.5561

30-mer G3
0
0
2.0361
3.1557
3.4296

p50BD protein-free sample corresponded to lane 1 on the gels shown in Figure 2.14 and
Figure 2.15; the pattern followed that lane 2 up to lane 10 increased in increments of
0.457 µM p50BD protein, such that lane 2 was 0.457 µM, lane 3 was 0.914 µM and so
forth as indicated in the figure legends.
Interaction of the 30-mer κB DNA sequences with p50H67A, mutant protein:
1 2 3 4
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Figure 2.16: 30-mer control κB DNA and p50H67A.
Lanes 1-10: DNA (0.26 µM) + p50H67A (0, 0.457, 0.914, 1.371, 1.828, 2.285, 2.742,
3.199, 3.656, and 4.11 µM protein).
Lane 12: single stranded control DNA, 2x concentration (0.56 µM).
The mutant p50 protein, p50H67A, was incubated with 30-mer κB DNA
sequences. A nearly 100% shift of the DNA is accomplished using 2.356 µM p50BD
protein (lane 6) as evaluated by Kapp (Table 2.5, page 46). Indeed, a 2.5-fold increase is
required in p50H67A protein amount as compared to p50BD protein to fully shift all
DNA (compare Figure 2.14 to 2.16).
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Interaction of the 30-mer κB DNA sequence modified at position G1 with p50H67A:

B

A

Figure 2.17: 30-mer G1 κB DNA and p50H67A.
Lanes 1-10: dsDNA (0.26 µM) + p50H67A (0, 0.457, 0.914, 1.371, 1.828, 2.285, 2.742,
3.199, 3.656, and 4.11 µM protein)
Lane 12: single stranded control DNA, 2x concentration (0.56 µM)
Gel shifts of the 8-oxoguanine modification at G1 for the 30 base pair oligomer
Figure 2.17 shows that the protein binds better to the control strand than to the modified
strands. There appears to be nearly a 100% gelshift by 2.827 µM p50H67A incubated
with G1 modified 30-mer compared to 2.356 µM protein required to shift unmodified 30mer DNA. Table 2.5 indicates that the binding of p50H67A is slightly worse for the G1
8-oxoguanine modified than that for the 30-mer control DNA.
If the histidine in position 67 is critical for binding class I κB DNA sites, a
difference in binding affinity should be observed between the 30-mer control with p50BD
and p50H67A (see Figures 2.14 and 2.15). The difference in binding affinity was around
2.5-fold, which seems indicative of a role for histidine 67 in binding to the consensus
sequence. The mutant was not pursued further; the results indicated that the importance
of the mutation, shown in terms of binding affinity, was not as dramatic as it would have
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been if the histidine position at 67 was critical for making bonds to non-modified and
modified κB DNA.
Table 2.5: Densitometry for 30-mer κB sequences and mutant p50H67A
% of DNA shifted by p50BD
lane p50H67A (µM)
control
8-oxoG1
1
0
2.6224
0
2
0.457
29.1754
0
3
0.914
67.3939
0
4
1.371
87.2181
14.3406
5
1.828
87.9168
35.6470
6
2.285
99
35.6470
7
2.742
99
99
From Table 2.5, zero µM p50H67A protein corresponded to lane 1 on the gels shown in
Figure 2.16 and Figure 2.17; the pattern followed that lane 2 up to lane 10 increased in
increments of 0.457 µM p50BD protein, such that lane 2 was 0.457 µM, lane 3 was 0.914
µM and so forth as indicated by the figure legends.
The NF-κB proteins are flexible in their binding; this is demonstrated by the
mutant p50H67A protein, which was capable of binding the κB DNA consensus site.
Nonetheless, it is known that these small differences in binding affinities for κB
sequences can have an impact on the expression of genes. Perhaps the importance of the
different binding affinities can only be seen in vivo. This leaves the door open to the
possibility that the role of the DNA sequence, any modifications, and DNA conformation
has an important regulatory responsibility in gene expression with the NF-κB protein
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Discussion:
The p50 binding domain, residues 23 to 366, and a single amino acid mutation of
histidine 67 to alanine 67 were cloned as an N-terminal his6-tagged protein. These
proteins were expressed and purified as active proteins.
The effect of 8-oxoguanine at each guanine site in the consensus sequence of κB
DNA on the binding affinity of p50BD was determined on a 22-mer and a 30-mer doublestranded DNA oligonucleotide containing the NF-κB binding site with modifications at
guanine sites (Figure 2.9 – Figure 2.13). The addition of a carboxyl moiety at position 8
on guanine (creating 8-oxoguanine) changes the binding affinity for the κB sequence. It
has been seen that the non-modified control binds the p50 binding domain homodimer
better than certain 8-oxoguanine modified κB DNA at specific sequences. Both 8oxoguanines G2 and G4 modified DNA binds with an affinity better than that of nonmodified control κB DNA. The 8-oxoguanine G2 has an interesting binding pattern with
the presence of dual binding bands (Figure 2.11) which indicates that monomeric p50BD
binds initially, and that at higher protein concentrations, the p50BD dimer can bind. It
has been proposed that the loss of a hydrogen bond donor-acceptor pair from the arginine
R59 of p50BD to the N7 (modified) of 8-oxoguanine G2 accounts for the loss of the p50
binding affinity (see Figure 2.2, page 23).
Earlier work investigated the apparent dissociation constants (Kapp, Table 2.6, p49)
of a full length dimeric p50 protein (Promega) with 8-oxoguanine modified κB sites.
From the early work, the relative Kapp for the unmodified control was found to be 0.672
µM with little change in the 50% binding affinity observed with the 8-oxoguanine
modifications at G2 and G4 for the 22-mer. Additionally, the 8-oxoguanine modification
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at G3, showed a nearly 4-fold decrease in Kapp for binding of the p50 subunit to this
modified DNA sequence versus the unmodified DNA sequence. Earlier work with 8oxoguanine G3 modified κB DNA and lowered p50 binding affinity suggested that this
modification can cause recognition loss of one of the κB DNA half sites.9 This
relationship appears to be true for the truncated p50 monomeric protein, p50BD, as well.
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Figure 2.18: Data taken from Table 2.3. Kapp binding for 22-mer κB DNA
oligonucleotide sequences and p50BD. There are no error bars as the one gel considered
the ‘best’ of each sequence was analyzed by densitometry.
It was found that the clone p50BD protein behaved in a manner analogous to the
full length Promega p50 protein with the same oligomer sequences, with the exception of
the 22-mer modified at G1. In fact, the p50 binding domain-only protein had apparent
binding affinity of 0.605 µM compared to the binding affinity of 0.672 µM for full-length
dimer protein (see Table 2.6) for control κB DNA. With modified κB DNA sequences,
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the truncated monomeric p50 protein, p50BD, retains the ability to interact in a manner
similar to the full-length dimeric p50 protein. The fewer number base pairs in the
engineered protein (consisting of the binding domain only), consequently results in fewer
potentially stabilizing amino acid residues. However, the lack of a few amino acid
residues apparently does not greatly impact the protein’s stability upon binding κB DNA.
Table 2.6: Binding affinities of the 22-mer control and 8-oxoguanine modified DNA
with p50 binding domain and p50 (whole protein). p50 data taken from Hailer-Morrison,
et al (2003) Biochem. 42, 9761-9770.9
Oligonucleotide
p50 binding domain only p50 (Promega, dimer)
Kapp binding affinity (µM)*
Kapp binding affinity (µM)*
Control
0.605
0.672 +/- 22
8-oxo-dG at G1
1.849
0.283 +/- 7
8-oxo-dG at G2
0.405
0.644 +/-35
8-oxo-dG at G3
10.69
2.340 +/- 40
8-oxo-dG at G4
0.498
0.550 +/- 35
* The Kapp for the non-modified control and 8-oxoguanine modified oligonucleotides
were determined graphically as the point where the percent bound was 50%.
For binding affinity, a lower number indicates a better binding of protein to DNA,
and a higher number indicates a poor affinity of protein for DNA. The binding affinities
above in the column “p50 binding domain only” were calculated assuming that the molar
ratio of dsDNA to protein was 1 to 1 as compared to the earlier work with dsDNA to fulllength p50 protein ratio at 1 to 2. For half-site binding, when comparing the 22-mer
control DNA binding with p50BD to the binding of modified oligonucleotides with
p50BD, it was seen that the binding affinity was best for the 8-oxoguanine modified at
G2, then G4, and then followed closely by the control DNA. When comparing p50BD
protein binding to control κB DNA (Figure 2.9, Kapp = 0.605 µM) with p50BD with 22G1
modified κB DNA (Figure 2.10, Kapp = 1.849 µM) it is seen that the truncated p50BD
protein has a poorer affinity for modified DNA at the G1 position. This result is in direct
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contrast to that of the whole p50 protein; 8-oxoguanine modified at G1 had a better
binding affinity (0.283 µM) than control DNA (0.672 µM) for the Promega p50 dimer.
The EMSA for 22G2 showed two DNA-protein binding bands with a higher
concentration of protein (Figure 2.11) due to the p50BD binding as either a monomer or a
dimer to the κB DNA. The results indicate that the protein binds independently as a
monomer for lower p50BD—DNA concentrations (Figure 2.11, arrow B) however, given
enough p50BD protein, ~ 2.356 µM, the 22-mer 8-oxoguanine G2 modified DNA will be
bound at both κB sites with two p50BD monomers – giving a dimer protein (see arrow C,
Figure 2.11). A 100% shift was observed with the putative monomeric protein.
Integration was based on arrow B, the monomer; further calculations for higher protein
concentration integration involved the addition of the two shifted bands (arrow B and C,
Figure 2.11). Work with the whole protein indicated no such dual banding with 8oxoguanine modified at G2, however the concentration of protein was 2 µM or less,
which is perhaps not enough protein to cause a dual banding.
The EMSA for the 22G3 showed that the modification negatively impacts DNA
binding, with an extrapolated by linear regression Kapp of 10.69 µM (Figure 2.12). This
loss of binding, reflected in a higher Kapp values, was proposed to be due to loss of the
half site of the κB DNA. The greatest percentage of protein bound to DNA was
determined to be 23%, thus the Kapp at 50% bound DNA-protein was never achieved and
was extrapolated graphically (50% bound DNA-protein = 4.318603143x + 3.820307386,
where x = Kapp (µM)). The poor binding with 8-oxoguanine modified at G3 is in
agreement with the trend seen with whole p50 protein.
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Comparing the 22-mer modified G4 (Figure 2.13) to control κB DNA (Figure
2.9), it was observed that the modified κB DNA requires less p50BD protein to exact a
complete shift. This is based on the assumption that twice the concentration of DNA
requires twice the concentration of protein to gel shift. The Kapp values were quite close
for binding affinities for the G4 and the control; more gels evaluated by densitometry
could possibly determine if this relationship is valid and that there is a slight but distinct
difference between the two oligonucleotide sequences.
Taken as a whole, these results indicate that the recognition of κB DNA by p50BD
decreases with 8-oxoguanine modification except for at the G2 and G4 positions.
Furthermore the loss in binding affinity is most dramatically seen with modification at
G3. The 8-oxoguanine modification has the least amount of impact with modifications at
G4 having a Kapp similar to the Kapp for control. The most interesting interactions
between DNA and protein are seen with the 8-oxoguanine G2 modification where the
protein can be visualized binding as both a monomer (Figure 2.11, arrow B) and as a
dimer (arrow C).

DNA-p50H67A (mutant protein) interactions
The binding of p50H67A with 30-mer κB control DNA was performed to
determine the importance of the histidine in position 67 of the human p50 protein. A
difference was observed between the binding of p50BD protein and p50H67A protein to
κB DNA (see Figures 2.14 and 2.16); the p50BD has greater affinity for the 30-mer
control sequence and the 8-oxoguanine modified G1 sequence than the p50H67A
(Kappp50BD = 0.386 µM versus Kappp50H67A = 0.707 µM for control κB DNA). The
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histidine in p50BD protein makes potential contacts with the G1 which accounts for the
difference in binding of 1.755 µM versus 2.391 µM when comparing p50BD and
p50H67A binding to 8-oxoguanine modified at position G1. The histidine to alanine
mutation allows the p50H67A protein to mimic the p65 (RelA) protein, which prefers a 9
base pair sequence. The anticipated result was that the mutant p50H67A would not bind
the 30-mer κB DNA sequence or would bind extremely poorly and would be reflected in a
high numeric value for the Kapp. Thus the slightly diminished binding affinity was not
significant enough to confirm that the histidine (H67) is critical for binding modified κB
oligonucleotides. Perhaps the binding affinity would be significant in vivo.
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Figure 2.19: Data taken from Table 2.4 and Table 2.5; Kapp for 30-mer κB DNA
oligonucleotide sequences with p50BD or p50H67A. No error bars were included as only
the one best gel of each sequence was analyzed by densitometry.
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Table 2.7: Binding affinities of 30-mer control and 8-oxoguanine modified DNA with
p50BD (binding domain) and p50H67A (mutant)

P50BD

P50H67A

Oligonucleotide

Kapp binding affinity Oligonucleotide
Kapp binding affinity
(µM)*
(µM)*
Control
0.386
Control
0.707
8-oxo-dG at G1
1.755
8-oxo-dG at G1
2.391
8-oxo-dG at G2
2.690
8-oxo-dG at G2
n/d
8-oxo-dG at G3
22.94
8-oxo-dG at G3
n/d
* The Kapp for the non-modified control and 8-oxoguanine G1 modified oligonucleotides
were determined graphically as the point where the percent bound was 50%. The Kapp for
the 8-oxoguanine modifications to G2 and G3 bound with p50BD were extrapolated by
linear regression. n/d indicates that the relationship was not determined.
The p50H67A was also able to bind the 30-mer κB DNA 8-oxoguanine modified
at position G1. It was predicted that the 8-oxoguanine containing DNA modified at G1
would bind the mutant protein differently as compared to the unmodified κB DNA. 8oxoguanine, with its increased number of donor/acceptor contacts (see Figure 1.3 A & B,
page 7) could potentially stabilize protein bonding to DNA modified at position G1 by
hydrogen bond/electrostatic contacts to the mutant protein. The possible areas for
contact include the carboxyl moiety of the protein backbone from alanine 67 to glycine 68
as a hydrogen bond acceptor from the hydrogen of N7 of 8-oxoguanine and arginine 59
NH2 as hydrogen bond donor to the carboxy at C8 of 8-oxoguanine. The values for the
mutant protein binding to 8-oxoguanine G1 were expected to have lower Kapp values
indicating a greater binding affinity as compared to the Kapp values for 8-oxoguanine
binding to p50BD. This predicted relationship was not observed, and it is possible that
the 8-oxoguanine at G1 does not make the predicted contacts to protein to stabilize
binding. A crystal structure of the mutant protein bound to κB DNA (non-modified and
modified) would clarify the DNA-protein interactions.
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It was seen that the binding affinity for the p50BD versus p50H67A in binding to
control κB DNA was around 2 -fold difference. Taking all the information together, these
results suggest that the histidine H67 is important in binding class I κB DNA. While
conserved for this consensus sequence, this amino acid is not shown to be critical for
binding a small oligonucleotide sequence, as there is a level of binding visible (Figure
2.16 versus Figure 2.14). This could be the result of the inherent flexibility of the protein
which still allows for DNA binding even if the sequence is not ideal (containing the class
I κB site of 5’-GGG RN-3’ half-site, where R is purine and N is any nucleotide).
Comparing the 8-oxoguanine modifications made to κB DNA and control κB DNA, the
results indicate that the p50BD protein binds better to non-modified DNA and perhaps
modifications to DNA by an oxidative mechanism is not necessarily a secondary form of
transcriptional regulation in the genome. Clarifications to this theory could be determined
by using a histone-wrapped full length gene with this exact consensus sequence κB DNA
to mimic in vivo DNA-protein actions. It is possible that the DNA-wrapped histone
confers protective shielding to sites on DNA susceptible damage and/or protein binding.
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CHAPTER 3
DNA-protein with chromium exposure could lead to crosslinking:
Background on previous work:
The five different κB DNA sequences, non-modified and modified at guanine
positions, for the 22-mer, 5’-AGT TGA G1G2G3 G4AC TTT CCC AGC C-3’, have been
shown to have discrete binding affinities for the p50 binding domain protein and
p50H67A protein. The 30-mer oligomer sequence, 5’- TCC GCT G1G2G3 G4AC TTT
CCG CGG AGA CTC TAG-3’, contains a slightly different flanking regions, however
the consensus sequence (bold) remains the same. These oligonucleotide κB DNA
sequences of 22 and 30 base pairs were used to explore the complex interactions of
oxidized DNA and p50BD protein with chromium treatment.
Previous work has established that, by reduction and oxidation potentials, it is
energetically favorable to further oxidize 8-oxoguanine-modified DNA while reducing
chromium(VI) if the two species are together in solution. If water acts as a nucleophile,
an additional oxidative event generates guanidinohydantoin (Gh) and
spiroiminodihydantoin (Sp) (see Figure 1.5, page 9). When protein is bound to modified
DNA it can potentially exclude or out-compete the water. Thus while chromium is
reduced in an oxidative event, and protein acts as a nucleophile, the oxidation of DNA
could crosslink the DNA—protein together in a covalent bond. This covalent
crosslinking of DNA and protein would establish a new mode of chromium toxicity with
damaged DNA.
Amino acids of interest in forming covalent bonds with any of the four different
8-oxoguanine modified bases in the κB DNA oligonucleotide are at the consensus site of
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the p50BD protein; these include arginine 57, arginine 59, tyrosine 60, histidine 67,
glutamate 60, and lysine 244 (Figure 3.1, taken from Huang et al., and 1SVC from the
Protein Data Bank; murine p50 - amino acids relative positions are three less base pairs
compared to human p50).1

G4

G3

G2

G1

Figure 3.1: Half site binding of p50 with DNA (4 guanine sequence)
Taken from Huang, et al. (2003) Proc. Natl. Acad. Sci. 100, 9268-9273. 2,3
The potential areas of binding include, but are not limited to the G1 of κB DNA
with histidine 67 (H64) of p50BD protein and G4 of κB DNA with lysine 244 (K241) of
p50BD protein (Figure 3.1). The functional group of histidine is the imidazolium moiety,
with two nitrogens available for chemical interactions. Histidine has a pKa = 6.0, which
means that at pH 6.0 half of the molecules are charged, and histidine is neutral on the
basic edge of physiological pH range, 6.5 to 7.6.4, 5 Thus histidine often contributes
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hydrogen bonds in enzymatic reactions. The lysine is available to form a Schiff base
through the distal amine depending on solution conditions. At physiological pH it is
positively charged with a pKa = 10.54. The arginines, with their available nitrogen
groups, are in close proximity to guanines 2 and 3 (G2 and G3, Figure 3.1). These amino
acids are also able to form Schiff base bonds with the pKa = 12.48 for the guanidinium
moiety.4
The amino acids listed above have the potential to act as nucleophiles on 8oxoguanine modified DNA competing with water which is a relatively poor nucleophile.
The nucleophile can attack the C5 position on the guanine (see Figure 2.2, page 23) and
attach to the nucleic acid moiety.
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Materials and methods:
Deoxyribonucleotides. Unmodified oligonucleotides with the κB consensus sequence
were obtained from IDT DNA (Coralville, IA). Modified 22-mer DNA sequences
containing an 8-oxoguanine in the NF-κB protein p50 homodimer consensus sequence
(5’-AGT TGA G1G2G3 G4AC TTT CCC AGC C-3’, where the bold bases indicate the
consensus sequence and the G1-4 indicate positions of 8-oxoguanines in the recognition
sequence) were obtained from TriLink Biotechnologies (San Diego, CA). Modified 30mer DNA sequences containing the sequence 5’- TCC GCT G1G2G3 G4AC TTT CCG
CGG AGA CTC TAG -3’ (again the bold bases indicate the consensus sequence and the
G1-4 indicates positions of 8-oxoguanines in the recognition sequence) were also obtained
from TriLink Biotechnologies. HPLC purification of the 22-mer oligonucleotide strands
was performed using a Dionex DNAPac PA-100, 4 mm x 250 mm anion exchange
column. Elution was accomplished with a linear gradient of 90% mobile phase A (10%
aqueous acetonitrile) and 10% mobile phase B (1.5 M ammonium acetate (pH 6.2), 10%
acetonitrile) to 100% mobile phase B over the course of 22 minutes. The 30-mer
oligonucleotide was purified in a similar manner, however mobile phase A also contained
500 mM NaCl and elution was accomplished with a linear gradient of 90% A and 10% B
to 100% mobile phase B over 30 minutes. Column elutions of oligonucleotides were
observed by diode array at 268 nm. The single-peak elution of oligomer was evaporated
to remove the volatile acetonitrile, eluted through a BioRad chromatography column 6
and stored at -20˚C until needed for testing. The NaCl from the 30-mer oligonucleotides
was removed by elution through a BioRad chromatography column 30. Standard
methods were employed to 5’- 32P end-label specific oligomers. The control or 8-
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oxoguanine containing single stranded DNA was incubated with polynucleotide kinase
and 10 µCi of 32P-γ-ATP for 30 minutes. Column elutions with a Micro Bio-Spin 6
chromatography column from BioRad (Hercules, CA) removed the enzyme and
unincorporated nucleotides. The radiolabeled single stranded DNA was annealed to
complement DNA by heating to 95˚C and slowly cooling 1˚C / 1 minute using a Peltier
Thermal Cycler from MJ Research (BioRad, Waltham, MA).
NF-κB p50BD Transcription Factor Protein. The p50 binding domain sequence from
residues 23 to 366 was created as described in chapter 2 by cloning into the pPROEX
HTa II plasmid to give the protein as an N-terminal His6-tagged protein.
Protein purification. The expression plasmids, in BL21 (DE3) cells, were grown to an
OD600 of 0.3-0.6 at 37˚C in LB media containing 25 µg/mL ampicillin, as the pPROEX
HTa contains an ampicillin resistance cassette. Cells were induced with IPTG to a final
concentration of 0.1 mM and incubated for 4 hours at 37˚C. Cells were then harvested by
centrifugation at 4˚C and 5,000 rcf, and frozen at -20˚C for later use. After thawing on
ice, cells were lysed using the BugBuster® protocol and reagent (Novagen, 5 mL reagent
per gram wet cell paste), lysozyme (Sigma, 0.5 mg per gram wet cell paste), Benzonase
nuclease (Novagen, 1 µL per mL BugBuster® reagent), and protease inhibitor cocktail
(Roche, 1 tablet dissolved in 2 mL H2O, use 0.2 mL per 5 mL extraction reagent). Cell
lysate was filtered through a Ni-NTA column (Qiagen). Protein was washed with
Solution A and B (50 mM NaH2PO4, 300 mM NaCl, with 10 mM and 20 mM imidazole
respectively) and eluted with Solution C (50 mM NaH2PO4, 300 mM NaCl, 250 mM
imidazole). The elution fraction was de-salted using a Microcon YM-10 and eluted into
protein storage buffer (20 mM HEPES, 50 mM NaCl, pH 7). An aliquot was reserved for
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BCA protein concentration analysis (BCA kit, Pierce, Rockford, IL), and the remaining
sample was diluted in half with protein storage buffer containing 40% glycerol, aliquoted
into sub-samples, and stored at -80˚C.
Chromium(V)-Salen. Three mg chromium(III)-Salen were dissolved in 300 µL dry
acetonitrile (20 mM chromium(III)-Salen). Three mg iodosyl benzene were added to the
solution and incubated for 30 minutes. The solution (chromium(V)-Salen) was diluted to
appropriate concentrations and used immediately.
HPLC shift Assay. DNA-protein binding reactions were performed using 50 µM 5’-DNA
which had been annealed to its complement to create double stranded DNA (dsDNA) and
approximately 32 µg p50BD protein. The reaction buffer for the DNA-protein binding
was 5 µL Buffer A (20 mM HEPES, 50 mM NaCl, pH 7) and Buffer B (Promega: 20%
glycerol, 5 mM MgCl2, 2.5 mM EDTA, 2.5 mM DTT, 250 mM NaCl, 50 mM Tris-HCL,
pH 7.5, 0.25 mg/ml poly(dI-dC)) to a total volume of 100 µL. The DNA and protein
were allowed to react for 20 minutes before chromium(V)-Salen was added (at varying
ratios to DNA, frequently 1:1,1:2, 1:5, 1:10, and 1:100) and incubated for 30 minutes at
room temperature. A cation exchange column, engineered by glass pipette, glass wool,
15 mg CM-Sephadex C-25-120 Resin (Sigma), and 200 µl H2O, removed the cationic
chromium from the DNA-protein solution. The DNA-protein sample was dried to 15 µL
for sample injection onto the HPLC. The concentrated sample was injected onto a
Dionex DNAPac PA-100, 4 mm x 250 mm anion exchange column. Elution was
accomplished with a linear gradient of 90% mobile phase A (10% aqueous acetonitrile)
and 10% mobile phase B (1.5 M ammonium acetate (pH 6.2), 10% acetonitrile) to 100%
mobile phase B over the course of 22 minutes. Later HPLC shift assays used only

62
reaction Buffer A with concentrated p50BD protein and DNA to a total volume of 10 µL
after chromium(V)-Salen addition. The sample cleanup on the cation exchange column
and HPLC sample injection was performed as described above.
Electromobility Shift Assay (EMSA or gelshift). DNA-protein binding reactions were
performed using 2.6 µM 5’-32P radioactive-labeled DNA which had been annealed to its
complement to create double stranded DNA (dsDNA). The reaction buffer for the DNAprotein binding was 300 mM NaH2PO4. When carrying out an EMSA on a
polyacrylamide gel; either a native 4% polyacrylamide gel was poured (with or without
urea), or a 6% Invitrogen pre-poured DNA retardation gel was used. The denaturant used
was 8 M urea added to the sample or added to the gel, heat, a combination of both. The
DNA and protein were allowed to react for 20 minutes before running on the gel.
Additionally, glycerol (1 µL, 40%) was added to all reaction mixes to increase density
and help with sample loading. Unless a free well was available for dye only, the sample
‘DNA only’ was the only well to have loading dye added in order to minimize any
interference of the dye with the DNA and protein binding interactions. The gels were run
at 250-300 V for ~10 minutes. The gel shifts were analyzed by autoradiography (Kodak).
Analysis of Reductively-trapped Schiff Base complexes of hOGG1. The chromium(V)Salen treated, 32P-labeled dsDNA (2.6 µM) was incubated with hOGG1 (15 nM, New
England Biolabs) in 10 µL reaction buffer (20 mM Tris-Cl (pH 8.0), 1 mM EDTA, 1 mM
DTT, 100 µg/mL BSA, 3 µL H2O) in the presence of 65 mM NaCNBH3 at 37˚C for 60
minutes. Glycerol (1 µL, 40%) was added to the sample. The gel shifts was analyzed as
described above. hOGG1 (38 KDa) is of comparable size to the p50BD protein (42.4
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KDa) for comparison of crosslinking. Visualization of this reductively-trapped crosslink
will indicate if it is possible to visualize oxidatively-trapped or crosslinked DNA-protein.
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Results
Covalent bonds are more resistant to degradation, meaning heat, urea, or similar
conditions that disrupt other bonds (ionic, van der Waals, or hydrogen bonds), and for
observation by HPLC these covalently bonded moieties could elute later or travel on a
PAGE gel as a single, larger complex than the DNA alone. An electrostatic bond of
DNA--protein will not remain as a single peak in HPLC system nor as a single DNAprotein band under rigorous denaturing conditions in a gel system.
The HPLC purification provides an elegant method to separate forms of modified
DNA. Modifications to DNA such as Gh and Sp can be resolved from 8-oxoguanine
even at higher ratios of 1:100, DNA : chromium (Figure 3.3). Therefore modifications to
DNA, such as a covalent protein linkage could also be resolved on HPLC as compared to
an 8-oxoG modification.6 Figure 3.3 shows Gh/Ia tautomers at peaks 1 and 2, the 8-oxoG
at peak 3, peak 4 is Sp, and peak 5 is an unidentified further oxidized species.

8-oxo DNA

Figure 3.3: HPLC trace of water as nucleophile on 8-oxoguanine exposed to chromium
Trace Blue = 8-oxo DNA, Trace Red = Cr(V)-Salen treated 8-oxoguanine.
Peaks 1 & 2 – Gh/Ia, tautomers, Peak 3 – 8-oxoG, Peak 4 – Sp
Peak 5 – further oxidized 8-oxoGox, Ghox or Spox, ratio of DNA to Chromium is 1:100.
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In Figure 3.4, for the ‘DNA + p50BD + chromium’, the DNA was incubated with
p50BD protein for 20 minutes before a 30 minute chromium(V)-Salen exposure. The
electrostatically bonded ‘DNA + p50BD’ (red) looks very similar to the ‘DNA + p50BD
+ chromium’ (magenta); crosslinking would create a system resistant to degradation, and
covalently bonded DNA–protein should elute at a different time than electrostatically
bonded DNA--protein. Perhaps the p50BD protects the oxidized DNA from further
oxidation or there was not enough protein to successfully bind and shift the DNA on the
HPLC, or it was lost in the clean-up process. The trace of ‘8-oxo DNA + chromium’ in
Figure 3.4 (green) is the same sample composition as the ‘8-oxo DNA + chromium’
from Figure 3.3 (red), however, the DNA:Cr ratio is 1:1, the peaks for Gh/Ia appear less
resolved and no Sp peak is detected. A higher ratio of chromium, such as 1:2 DNA to
chromium, would create more Gh/Ia and Sp for improved peak resolution. The DNA
sample with protein and chromium is not distinctly different than the DNA + chromium
sample, however, previous work at higher chromium concentrations indicated that the
protein shields the DNA from chromium damage.7 It is possible that the cation exchange
column contributed to a small loss of DNA in samples placed on the HPLC. If a covalent
crosslink had occurred and was detected by the HPLC, it is possible that the complexes’
charge might be different thus there would be a DNA-p50BD complex eluting at a
different time in the magenta trace, and this was not observed.
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Figure 3.4: HPLC trace of 8-oxoguanine with and without protein, and with chromium
Controls: Blue-ds-8-oxoguanine DNA only; Red- 8-oxoguanine dsDNA + p50BD;
Green- 8-oxoguanine dsDNA + chromium; 8-oxoguanine DNA + p50BD;
Sample: Magenta- - 8-oxoguanine DNA + p50BD + chromium;
* Initial amounts of DNA were the same, HPLC traces are offset for comparison
It was determined that the HPLC, as set up with an anion exchange column, was
not the optimal setting for determining covalent DNA-protein bonding. One system that
required less DNA and less protein was a polyacrylamide gel using radiolabeled DNA.
Electrophoretic gel shift assays of DNA-protein were performed to determine Kapp values
for binding affinities for the five 22-mer modified and unmodified κB DNA sequences
(chapter 2).
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Figure 3.5: Gel comparison of control vs. 8-oxoG DNA with and without chromium
Lanes 1-6 unmodified DNA, Lanes 7-12 8-oxo G1 DNA
LÆR the samples are DNA, DNA + protein, DNA + protein with urea, DNA +
chromium, DNA + protein + chromium, and DNA + protein + chromium with urea.
*Denaturant (8 M urea) in lanes 3, 6, 9, and 12
In Figure 3.5, control DNA, 22G0, is in lanes 1-6 and 8-oxoG modified at
position 1, 22G1, is in lanes 7-12; the protein is p50BD. The sample types are DNA
(lanes 1, 7), DNA + p50BD (2, 8), DNA + p50BD denatured (3, 9), DNA + chromium (4,
10), DNA + p50BD + chromium (5, 11), and DNA + p50BD + chromium denatured (6,
12).
For the non-modified strand, if a covalent crosslink formed, it would show in lane
6 (Figure 3.5, DNA-Protein complex row) with no free oligomer DNA strand (lane 1) as
covalent crosslinks are typically resistant to denaturing. If the non-covalent linkages, like
electrostatic bonding of DNA--protein were subjected to denaturing (lane 3), and were
not resistant to denaturing, all DNA would show as a DNA only band. However the
electrostatic DNA-protein bond remains resistant to denaturing (compare lanes 2 and 3).
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This resistance to denaturing suggests that the conditions for denaturing are not harsh
enough to break the hydrogen bonds.
If a crosslink had formed in the modified strand, it would show up in lane 12
(DNA-protein complex row, Figure 3.5) with a limited amount, or no, free oligomer
strand (DNA only row). The denatured DNA + protein (lane 9) would revert to the DNA
only lane and not resemble that of to the DNA + protein (lane 8). The DNA + protein +
chromium samples (lane 12) would not be affected by denaturing conditions if the bond
was covalent. Adding a denaturant, 8 M urea (Figure 3.5), to DNA + protein +
chromium only slightly disrupts DNA-protein binding in the case of modified DNA.
Adding heat (50˚C, 10 min) to denature DNA-protein bonds effectively removes the shift
lane for those samples subjected to denaturing conditions (lanes 3, 6, 9, 12, Figure 3.6).
22G0

bottom of

22G1
DNAProtein
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Figure 3.6: Gel comparison of control vs. 8-oxoguanine G1 DNA with and without
chromium using heat and 8 M urea as a denaturant of p50BD and κB DNA on a 4%
PAGE gel.
Lanes 1-6 unmodified DNA, Lanes 7-12 8-oxo G1 DNA
LÆR the samples are DNA, DNA + protein, DNA + protein with urea, DNA +
chromium, DNA + protein + chromium, and DNA + protein + chromium with urea.
*Denaturant (8M urea) in lanes 3, 6, 9, and 12
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In Figure 3.6, the samples are in the same order as Figure 3.5.

The chromium-

free control sample (22G0 + p50BD) appears to be more resistant to heat and urea for the
non-modified DNA, when comparing DNA bound to p50BD under denaturing conditions
(lane 3) versus DNA bound to p50BD with chromium under denaturing conditions (lane
6). However, for modified DNA, urea (8 M) appears to affect DNA bound to p50BD
subjected to denaturing conditions with and without chromium (lane 9 versus lane 12)
similarly. The denaturing conditions are perhaps too harsh for unmodified DNA and
DNA 8-oxoguanine modified at position 1 as the denatured hydrogen bonds (lanes 3, 9)
are not distinctly different than their respective denatured chromium treated DNA-protein
bonds (lanes 6, 12). It appears that the arrow indicating the DNA-protein complex row
for sample 12 is very similar to the DNA-protein complex row for sample 9 which does
not clearly indicate a DNA-protein crosslinking by chromium.

bottom
of wells

DNA
protein
complex

bound DNA
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DNA

Figure 3.7: Gel of 8-oxoguanine G2 DNA with and without chromium using 8 M urea as
a denaturant of p50BD and κB DNA.
Lanes 1-3: DNA (0.26 µM), DNA + hOGG1 + NaCNBH3, DNA + chromium(V)-Salen
Lanes 4-9: DNA + p50BD (800 ng) + chromium(V)-Salen (0, 0.26, 0.52, 1.3, 2.6, 26 µM)
+ Urea
Lanes 10-11: DNA + p50BD + NaCNBH3, DNA + p50BD + chromium + NaCNBH3
On a 6 % DNA retardation gel

70
Figure 3.7 shows 8-oxoguanine modified at position G2 in κB DNA sequence
bound with protein subjected to chromium oxidation. Lane 1 is a control lane to
determine where unbound modified DNA travels on the gel. Lane 2 is the modified DNA
bound to hOGG1 (by borohydride trapping, see the arrow indicating bound DNA, Figure
3.7). The hOGG1 enzyme has N-glycosylase and AP-lyase activity.8 The hOGG1
enzyme can be reductively trapped on DNA with addition of NaCNBH3 through the
reduction of the Schiff base intermediate formed from lysine 44.9,10 The use of
reductively-trapped DNA—protein is a tool to determine if oxidatively-trapped DNA—
protein (crosslinks) can be visualized on this type of gel. Due to the higher percentage of
acrylamide for the gel in Figure 3.7 (6 %), a small amount of the radiolabeled DNAprotein treated with chromium or NaCNBH3 stayed in the wells (lanes 4-11). Unlike the
samples injected into the HPLC, the chromium was not removed from the samples before
running the gel and has a tendency to block DNA-protein migration into the gel. In
Figure 3.7, lane 3 is a control lane with DNA oxidized by chromium. Lanes 4 through 9
show DNA bound to p50BD protein subjected to increasing amounts of chromium.
There is no discernable crosslink which would result in a shift visible on the gel. Lane
10, with DNA, p50BD protein, and using NaCNBH3 as a reductant, gives a higher
molecular weight complex than the DNA-p50BD + Cr(V)-Salen band (lanes 4-9). It is
proposed that this corresponds to the formation of a p50BD homodimer bound to the κB
DNA sequence as seen in Figure 2.11, page 39. Lane 11, where DNA is bound to
protein, exposed to chromium, and subjected to NaCNBH3 reductant for crosslinking,
shows that the monomeric protein binding to DNA is restored (versus lane 10).
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Figure 3.8: Gel of 8-oxoguanine G3 DNA with and without chromium using 8M urea
and heat as a denaturant of p50BD and κB DNA
Lanes 1-2: DNA (0.26 µM), DNA + chromium(V)-Salen,
Lanes 3-4: DNA + p50BD (2500 ng), DNA + p50BD denatured (urea)
Lane 5: DNA + p50BD + chromium(V)-Salen,
Lane 6: DNA + p50BD + chromium(V)-Salen + urea,
Lane 7: DNA + p50BD + chromium(V)-Salen + urea (30 minute exposure),
Lane 8-9: DNA + p50BD + chromium(V)-Salen + 30˚C 5 min, Same with 60˚ C 5 min
Lane 10: DNA + p50BD + chromium(V)-Salen + urea + 30˚ C heat.
On a 4% urea gel
The p50BD protein has been shown to have poor binding to κB DNA when 8oxoguanine modifies position 3 (see Figure 2.12, page 40). Figure 3.8 shows the binding
of this G3 modified κB DNA (22G3) with p50BD, exposed to chromium and denaturing
conditions. DNA bound to protein binds almost the same whether it is subjected to 8 M
urea denaturing conditions (lane 4) or not (lane 3). Adding chromium and urea to the
DNA-protein binding has little impact (lanes 5-7). However adding heat as a denaturant
to the DNA-protein binding has great impact; even a gentle heat, 30˚C, completely
abolishes any binding (lane 8). This is consistent with the overall weaker binding of
p50BD to DNA 8-oxoguanine modified at this position.
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Discussion
The samples run on the HPLC to detect DNA-protein crosslinking did not confirm
or refute the presence of crosslinking. What was seen in Figure 3.4 was that the HPLC
traces containing DNA with and without p50BD protein and chromium were similar.
The two traces of DNA and chromium, one with and one without p50BD protein were
similar, probably due to the ratio of DNA to chromium (1:1). It was thought that the ratio
of 1:1 would be sufficient to see a difference between the samples. A higher amount of
chromium to DNA would improve the resolution of the Gh/Ia and Sp peaks as seen in
Figure 3.3. Earlier HPLC traces agreed with previous work that the p50BD protein
shielded the DNA from the oxidative effects of chromium (data not shown).
Nonetheless, a peak for the 8-oxoguanine DNA was determined to have eluted at the
same time for all traces (8.4 minutes). Parts of the solution, including any residual buffer
salt from the cation exchange column, elute quickly. Specifically, these peaks were seen
at 1.5 to 2.5 minutes.
It is possible that there was not enough protein to successfully bind the κB DNA
or that running the DNA-p50BD protein complex through the cation exchange column
disrupted some protein hydrogen bonds. The amount used was sufficient to cause a
100% DNA shift. Gel systems with 5’-32P radiolabeled double-stranded DNA can use a
much smaller amount of DNA to visualize interactions and there is no cation exchange
column requirement. On the HPLC, a small amount of protein will certainly bind the
DNA, yet an insufficient amount of protein might not clearly show the DNA-protein
complex shifted to a different retention time. This four-sample HPLC determination of
DNA-protein crosslinking was run earlier using a solution buffer with DTT and a higher
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ratio of chromium to DNA (1000:1) where the shielding effects of the protein were
visible by HPLC trace (data not shown). Figure 3.4 had no DTT in the sample
preparation; this last HPLC trace assumed that the DTT of 2.5 mM reduced the
chromium(V)-Salen (0.5 mM). It was determined that the HPLC separation based on
charge was not the correct system for visualizing DNA-protein crosslinks.
Modified 22-mer DNA and p50BD protein together are quite sizable (13.5KDa
and 42.4 KDa respectively) which can be a problem when using an older HPLC column.
Charge separation was not conclusive; thus a gel system was a better choice to determine
covalent crosslinking for whole protein—DNA. The benefits include a smaller
concentration of DNA can be radiolabeled with 32P-γ-ATP and still be visualized, and
there is no cation exchange column DNA loss as there is no clean-up required to remove
excess chromium for samples run on a gel.
For Figure 3.5, for unmodified DNA, lanes 1-6, the gel implies that chromium
oxidation could cause covalent crosslinking, but more harsh denaturing conditions are
required to prove the crosslinking. The non-modified DNA bound to protein and
subjected to chromium and denaturing conditions (lane 6) appears more resistant to
denaturing than DNA bound to protein and subjected to denaturing conditions (lane 3) as
determined by the amount of unbound DNA (see free DNA arrow). This result does
support the theory that a covalent bond is more resistant to degradation than an
electrostatic bond for DNA-protein crosslinking.
In Figure 3.5, for 8-oxoguanine modified at position G1 DNA implies that the
bond is not covalent when bound to p50BD protein and exposed to chromium. It seems
that DNA–protein subjected to chromium and denaturing conditions (lane 12) appears
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less resistant to denaturing to denaturing than DNA bound to protein and subjected to
denaturing conditions (lane 9). This implies that there was no covalent linkage of
modified DNA with p50BD protein and that the chromium was able to oxidize either the
DNA or the protein and decrease the electrostatic bonding of the DNA and protein as
evidenced by unbound DNA (see arrow ‘free DNA’ Figure 3.5). The DNA bound to
protein subjected to denaturing 8 M urea (lane 9) is less degraded than the sample of
DNA bound to protein not subjected to 8 M urea (lane 8) which indicates an unusual
relationship of urea with modified κB DNA and the truncated p50 protein. It is known
that the κB DNA is close to B-form DNA and that when the p50 protein binds to it, there
is only a slight unwinding in the 5’-GGGG-3’ area and a very small bend produced in the
DNA. It is possible that the 8-oxoguanine with p50BD protein bound is structurally
perturbed compared with unmodified κB DNA with p50BD bound, and adding urea to
the system disrupts non-specific protein binding, permitting the DNA to adopt a more Bform shape, which allows for the protein to bind tighter to the DNA. The bound DNAprotein complex bands remaining for the urea treated lanes, 3, 6, 9, and 12 suggests that
the denaturing conditions are not strong enough to break hydrogen bonds.
Increasing the denaturing by using mild heat had a drastic effect on the denatured
samples (Figure 3.6). For the unmodified DNA, it appeared that DNA bound to protein
exposed to chromium (lanes 6) was denatured more than the DNA bound to protein
(lanes 3), in direct contrast to what was seen in Figure 3.5. For 8-oxoguanine modified
DNA, the effects of denaturing the DNA-protein complexes with and without chromium
exposure were essentially the same (lanes 9 compared to 12) which was slightly different
from the pattern seen in Figure 3.5. The 8-oxoguanine G1 DNA incubated with protein
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and exposed to chromium and urea/heat had similar amounts of residual binding as well
as free (non-protein bound) DNA as the modified DNA incubated with protein and
exposed to urea/heat. It is possible that the tighter binding affinity of control DNA, 0.605
µM, compared to the binding affinity for 8-oxoguanine modified at position G1 DNA,
1.849 µM, with p50BD protein contributed to the variation of the effects of heat/urea on
the different κB DNA sequence (see table 2.6, page 49).
For κB DNA 8-oxoguanine modified at position G2 bound to p50BD protein
subjected to chromium oxidation (Figure 3.7), increasing amounts of chromium does not
appear to covalently link the DNA and the protein. In lane 10, DNA bound to protein
and exposed to sodium cyanoborohydride gives the dual banding pattern proposed to be
the p50BD homodimer seen in the EMSA, Figure 2.11, page 39. It is possible that the
NaCNBH3 reduced some of the p50BD protein strand and altered the binding of the
monomeric protein to DNA. The sample ‘DNA + p50BD + chromium + NaCNBH3’
mimicked the binding of the DNA-protein bands. It was seen earlier that as the amount
of p50BD protein increased past a certain concentration of protein (2.356 µM), the
p50BD began to bind as a proposed dimer. This could indicate that at higher amounts of
truncated p50 protein allosteric cooperative binding is possible. Without a crystal
structure of the truncated form of the p50 protein, it is difficult to determine the exact
effects of truncating the protein. It is possible that the amino acid residues not included
stabilized the full p50 protein at the dimerization interface, which is in the C-terminal
domain and has six variable loops.
When using κB DNA 8-oxoguanine modified at position G3, it was seen that
chromium and urea have little impact on binding of DNA and p50BD protein (Figure 3.9,
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lanes 4-7). The binding of the p50 was poor, regardless of any sample additions such as
chromium and urea. Adding heat as a denaturant was detrimental to binding; all samples
subjected to heat had no protein bound lane (Figure 3.9, lanes 8-10), as expected.
Taken together, these results indicate that no apparent covalent crosslinking
occurs with unmodified κB DNA and p50BD protein when subjected to chromium as an
oxidant. Furthermore, the above results indicate that 8-oxoguanine-modified at positions
G1 through G4 κB DNA sequences also do not covalently crosslink to p50BD protein.
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